AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

UPDATE: EMA has "not yet reached conclusion" on AstraZeneca vaccine

Tue, 6th Apr 2021 14:15

(Alliance News) - The EU's drug regulator said Tuesday it is still deciding whether the AstraZeneca PLC coronavirus vaccine causes blood clots, after a top official said there was a clear link.

The European Medicines Agency's safety committee "has not yet reached a conclusion and the review is currently ongoing", the Amsterdam-based EMA said in a statement to AFP.

"We will communicate and hold a press briefing as soon as the review is finalised. This is currently expected tomorrow (Wednesday, 7 April) or on Thursday, 8 April," it added.

The statement came after the EMA's head of vaccine strategy Marco Cavaleri was quoted in Italian media as saying that there was a "clear" connection and that the agency would announce it within hours.

"In my opinion, we can say it now, it is clear there is a link with the vaccine. But we still do not know what causes this reaction," Cavaleri told Italy's Il Messaggero newspaper in an interview.

After several countries suspended the use of the AstraZeneca jab, the EMA said on March 18 that the benefits of using it outweigh the risks and it should remain in use.

But it has said there is a possible link to rare blood clots and that it would issue updated advice during this week's meeting of its safety committee. 

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

UK to give under 40s alternative to AstraZeneca vaccine

(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.

7 May 21 09:49

All under-40s to be offered alternative to AstraZeneca vaccine

All under-40s to be offered alternative to AstraZeneca vaccine

7 May 21 08:49

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

7 May 21 08:32

AstraZeneca's Imfinzi demonstrates benefit in combination with antibody

(Sharecast News) - AstraZeneca reported on Friday that 'Imfinzi' and tremelimumab with chemotherapy demonstrated an overall survival benefit in the 'POSEIDON' trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.

7 May 21 07:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.